Beta and angiotensin blockades are associated with improved 10-year survival in renal transplant recipients.

9 – 10 , 13 The safety data on AB use in posttransplant period are very promising, 11 and there is an increasing trend of AB prescription, from <20% in the early 1990s to >45% in the 2000s. 28 – 29 The role of these agents in patient survival remains a matter of debate.

also in 63,971 other papers